Belite Bio (BLTE)

Executive Summary

Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting Retinol Binding Protein 4 (RBP4) for debilitating diseases such as Stargardt disease, geographic atrophy (GA), and metabolic disorders. Its lead asset, tinlarebant (LBS-008), is an oral RBP4 antagonist designed to reduce toxic vitamin A derivatives in the retina. In Stargardt disease, a Phase 3 trial (NCT05244304) completed in September 2025, and a pivotal Phase 2/3 study (NCT06388083) is ongoing with expected completion in 2028. For GA, a Phase 3 trial (NCT05949593) is actively enrolling, with completion anticipated in 2027. Positive data from these studies could position tinlarebant as a first-in-class therapy for these blinding conditions, addressing significant unmet medical needs. Belite Bio also has early-stage programs for liver disease and diabetes, leveraging its RBP4 platform. The company went public in 2022 and is headquartered in the United States, with a valuation of approximately $6.4 billion.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Stargardt Disease Data & Potential NDA Submission70% success
• Q2 2027Phase 3 Geographic Atrophy Interim Analysis60% success
• Q4 2026Initiation of Phase 2/3 for Diabetic Retinopathy or Liver Indication40% success